E. Piccolini
7 Papers
41 Citations
E. Piccolini is an academic researcher. The author has contributed to research in topics: Mesothelioma & Genome-wide association study. The author has an hindex of 5, co-authored 7 publications.
Chat about Author
Papers
Genetic Variants Associated with Increased Risk of Malignant Pleural Mesothelioma: A Genome-Wide Association Study
Giuseppe Matullo,Simonetta Guarrera,Marta Betti,Giovanni Fiorito,Daniela Ferrante,Floriana Voglino,Gemma Cadby,Gemma Cadby,Cornelia Di Gaetano,Fabio Rosa,Alessia Russo,Ari Hirvonen,Elisabetta Casalone,Sara Tunesi,Marina Padoan,Mara Giordano,Anna Aspesi,Caterina Casadio,Francesco Ardissone,Enrico Ruffini,Pier Giacomo Betta,Roberta Libener,Roberto Guaschino,E. Piccolini,Monica Neri,Arthur William Bill Musk,Arthur William Bill Musk,Nicholas de Klerk,Jennie Hui,John Beilby,Alan James,Alan James,Jenette Creaney,Jenette Creaney,Bruce W. S. Robinson,Bruce W. S. Robinson,Sutapa Mukherjee,Sutapa Mukherjee,Lyle J. Palmer,Dario Mirabelli,Donatella Ugolini,Stefano Bonassi,Corrado Magnani,Irma Dianzani +43 more
TL;DR: The results showed that genetic risk factors may play an additional role in the development of MPM, and that these should be taken into account to better estimate individual MPM risk in individuals who have been exposed to asbestos.
XRCC1 and ERCC1 variants modify malignant mesothelioma risk: A case–control study
Marta Betti,Daniela Ferrante,Marina Padoan,Simonetta Guarrera,Mara Giordano,Anna Aspesi,Dario Mirabelli,Dario Mirabelli,C. Casadio,Francesco Ardissone,Enrico Ruffini,Pg Betta,Roberta Libener,Roberto Guaschino,Giuseppe Matullo,E. Piccolini,Corrado Magnani,Irma Dianzani +17 more
TL;DR: The association of MPM with DNA repair genes support the hypothesis that an increased susceptibility to DNA damage may favour asbestos carcinogenicity.
Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects
Simonetta Guarrera,Clara Viberti,Giovanni Cugliari,Alessandra Allione,Elisabetta Casalone,Marta Betti,Daniela Ferrante,Anna Aspesi,Caterina Casadio,Federica Grosso,Roberta Libener,E. Piccolini,Dario Mirabelli,Dario Mirabelli,Irma Dianzani,Irma Dianzani,Corrado Magnani,Corrado Magnani,Giuseppe Matullo +18 more
TL;DR: The results provide the rationale to further investigate the potential use of blood DNA methylation profiles for the identification of early changes related to the MPM carcinogenic process and demonstrate the need for noninvasive early diagnostic tests to monitor asbestos‐exposed people.
30
Aurora B kinase and malignant mesothelioma.
Pier Giacomo Betta,T. Bensi,N. F. Trincheri,E. Arnolfo,Roberta Libener,M. Botta,E. Piccolini,G. Bottero,Federica Grosso,Sara Orecchia +9 more
TL;DR: An aggressive neoplasm of the serosal cavities, resistant to conventional treatment, for which new therapeutic targets are being actively sought is being actively pursued.
2
Outcomes of sarcomatoid malignant pleural mesothelioma, a distinct clinical entity.
Elisabetta Gattoni,Federica Grosso,Annalisa Roveta,Roberta Libener,D. Degiovanni,Maurizio Mancuso,E. Piccolini,Gabriele Ferretti,M. Botta,Pier Giacomo Betta +9 more
TL;DR: Sarcomatoid malignant pleural mesotheliomas, accounting for 10% of MPM, are resistant to chemotherapy (CT) with median survival in the range of 6 months, and here the authors report on four novel mechanisms leading to resistance to CT.
1